<DOC>
	<DOC>NCT01107054</DOC>
	<brief_summary>A study to determine the cardiovascular effects of PF00610335 in healthy volunteers.</brief_summary>
	<brief_title>A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male and female subjects aged 18 to 55 years Informed consent document signed by the subject or a legally acceptable representative Subjects who are willing and able to comply with the scheduled visits, treatment tests, laboratory tests, and other study procedures Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic psychiatric, neurologic or allergic disease or clinical findings at screening Conditions possibly affecting drug absorption 12lead ECg demonstrating QTc &gt; 450ms or any other clinically significant abnormalities at screen Positive urine drug screen Hypersensitivity to moxifloxacin or PF00610335 Unwilling or unable to comply with the lifestyle guidelines in the protocol Treatment with an investigational drug within 3 months or 5 half lives (whichever is longer) preceding the first dose of study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>QTC</keyword>
</DOC>